Literature DB >> 31176206

Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer.

Nikhil Sebastian1, Trudy Wu1, Erin Driscoll2, Henning Willers2, Suzanne Kelly3, Hima Bindu Musunuru4, Xiaokui Mo5, Yubo Tan5, Jose Bazan1, Karl Haglund1, Meng Xu-Welliver1, Andrew M Baschnagel4, Andrew Ju3, Florence Keane2, Terence M Williams6.   

Abstract

BACKGROUND: Tumor aggressiveness and hypoxia are linked to acidosis in the tumor microenvironment (TME). We hypothesized that low pre-treatment serum bicarbonate, potentially correlating with an acidic and hypoxic TME, predicts for poor outcomes after stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC).
METHODS: We included patients with localized NSCLC treated to a biologically effective dose (BED) ≥ 100 Gy, with available pre-treatment bicarbonate values within 3 months of treatment. We used receiver operating characteristic analysis to determine the bicarbonate concentration optimally predicting for primary tumor recurrence, and evaluated its association with recurrence and survival. We validated our findings in an independent cohort of patients from three collaborating institutions.
RESULTS: A total of 110 patients and 114 tumors were included in the training cohort, with median follow-up of 15.0 months. Bicarbonate < 26 mEq/L was associated with primary tumor recurrence on univariate (HR = 5.92; 95% CI 1.69-24.88; p = 0.005) and multivariate analysis (HR = 5.48; 95% CI 1.37-25.19; p = 0.020). The validation cohort consisted of 195 patients and 208 tumors with median follow-up of 27.5 months. In the validation cohort, bicarbonate < 26 mEq/L was again associated with primary tumor recurrence on univariate (HR = 3.38; 95% CI 1.27-9.37; p = 0.015) and multivariate analysis (HR = 3.33; 1.18-10.07; p = 0.023).
CONCLUSIONS: Pre-treatment bicarbonate predicts for primary tumor control in NSCLC treated with SBRT and may be useful for risk stratification. These findings should be confirmed prospectively.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bicarbonate; Non-small cell lung cancer; Primary tumor recurrence; Stereotactic body radiation therapy

Mesh:

Substances:

Year:  2019        PMID: 31176206      PMCID: PMC7080525          DOI: 10.1016/j.radonc.2019.05.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  59 in total

Review 1.  The effects of extracellular pH on immune function.

Authors:  A Lardner
Journal:  J Leukoc Biol       Date:  2001-04       Impact factor: 4.962

2.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  David S Ettinger; Douglas E Wood; Dara L Aisner; Wallace Akerley; Jessica Bauman; Lucian R Chirieac; Thomas A D'Amico; Malcolm M DeCamp; Thomas J Dilling; Michael Dobelbower; Robert C Doebele; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Leah J Leisch; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

Review 3.  The effects of acid-base disturbances on cardiovascular and pulmonary function.

Authors:  J H Mitchell; K Wildenthal; R L Johnson
Journal:  Kidney Int       Date:  1972-05       Impact factor: 10.612

4.  Systemic buffers inhibit carcinogenesis in TRAMP mice.

Authors:  Arig Ibrahim-Hashim; Heather H Cornnell; Dominique Abrahams; Mark Lloyd; Marilyn Bui; Robert J Gillies; Robert A Gatenby
Journal:  J Urol       Date:  2012-06-15       Impact factor: 7.450

5.  Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline.

Authors:  Gregory M M Videtic; Jessica Donington; Meredith Giuliani; John Heinzerling; Tomer Z Karas; Chris R Kelsey; Brian E Lally; Karen Latzka; Simon S Lo; Drew Moghanaki; Benjamin Movsas; Andreas Rimner; Michael Roach; George Rodrigues; Shervin M Shirvani; Charles B Simone; Robert Timmerman; Megan E Daly
Journal:  Pract Radiat Oncol       Date:  2017-06-05

6.  Radiosensitivity, blood perfusion and tumour oxygenation after perflubron emulsion injection.

Authors:  L Vitu-Loas; C Thomas; N Chavaudra; M Guichard
Journal:  Radiother Oncol       Date:  1993-05       Impact factor: 6.280

7.  Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress.

Authors:  Gregory Lamonte; Xiaohu Tang; Julia Ling-Yu Chen; Jianli Wu; Chien-Kuang Cornelia Ding; Melissa M Keenan; Carolyn Sangokoya; Hsiu-Ni Kung; Olga Ilkayeva; László G Boros; Christopher B Newgard; Jen-Tsan Chi
Journal:  Cancer Metab       Date:  2013-12-23

8.  Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer.

Authors:  Julia Dreyer; Michael Bremer; Christoph Henkenberens
Journal:  Radiat Oncol       Date:  2018-11-03       Impact factor: 3.481

9.  Arterial pH, bicarbonate levels and base deficit at presentation as markers of predicting mortality in acute pancreatitis: a single-centre prospective study.

Authors:  Vishal Sharma; Thingbaijam Shanti Devi; Ravi Sharma; Puneet Chhabra; Rajesh Gupta; Surinder S Rana; Deepak K Bhasin
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-07-03

10.  Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.

Authors:  Eric D Brooks; Bing Sun; Lei Feng; Vivek Verma; Lina Zhao; Daniel R Gomez; Zhongxing Liao; Melenda Jeter; Michael O'Reilly; James W Welsh; Quynh-Nhu Nguyen; Jeremy J Erasmus; George Eapen; Kamran Ahrar; Mara B Antonoff; Stephen M Hahn; John V Heymach; David C Rice; Joe Y Chang
Journal:  JAMA Netw Open       Date:  2018-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.